

## Special Issue

# Antithrombotic Treatment of Acute Coronary Syndrome

### Message from the Guest Editor

According to the ESC guidelines, individualization of DAPT could be done by using risk scores (PRECISE DAPT, and DAPT scores). These scores may also be useful for determining the duration of DAPT, which is another area of controversy in the field of ACS. The fast onset of action of antiplatelet agents is paramount in high-risk patients such as those presenting with ST-elevation myocardial infarction (STEMI). Even the stronger P2Y12 inhibitors prasugrel and ticagrelor fail to be active in the first hours of STEMI, and therefore, there is a need for the development of antiplatelet agents with very rapid onset. This Special Issue will summarize, among other topics, the current optimal ATT of ACS, the new antithrombotic treatments (cangrelor, selatogrel), how to individualize DAPT, controversies in the optimal ATT, and how to handle ATT when bleeding occurs.

- acute coronary syndrome
- antithrombotic therapy
- P2Y12 inhibition
- tailored therapy

### Guest Editor

Prof. Dr. Jurriën ten Berg

1. Interventional Cardiologist St Antonius Hospital, Nieuwegein, The Netherlands
2. Professor "antithrombotic therapy in cardiac catheter interventions" at University Medical Center Maastricht, Maastricht, The Netherlands

### Deadline for manuscript submissions

closed (30 September 2020)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/31780](https://mdpi.com/si/31780)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).